product name Gambogic Acid
628.75
Formula
C38H44O8
CAS No.
2752-65-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (159.04 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol:
Solubility (In vivo)
Chemical Name
2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, (2Z)-
other peoduct :References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19405022
Gambogic Acid is a caged xanthone that is derived from Garcinia hanburyi and functions as a strong apoptotic inducer in many types of cancer cells by inhibiting human Bcl-2 family proteins and activating caspases. Gambogic Acid also blocks Kir2.1 channels with EC50 of ≤ 100 nM. Gambogic Acid significantly inhibits human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion, tube formation, and micro-vessel growth at nM concentration. | |
---|---|
In Vivo | Gambogic Acid effectively inhibits tumor angiogenesis and suppressed tumor growth with low side effects using metronomic chemotherapy with Gambogic Acid. The results indicated that iv injection of GGA 2, 4, and 8 mg/kg inhibited dramatically the growth of human hepatocellular cell line SMMC-7721 in nude mice from the early administration. |
Animal model | BALB/c nude mice bearing SMMC-7721 xenografts |
Formulation & Dosage | Intravenous injection, 2, 4, and 8 mg/kg, 3 times per week |
References | Acta Pharmacologica Sinica, 2004, 25: 769-774. |
Author: Sodium channel
Share this post on:
Molecular Weight (MW)
628.75
Formula
C38H44O8
CAS No.
2752-65-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (159.04 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol:
Solubility (In vivo)
Chemical Name
2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, (2Z)-
product name Gambogic Acid
628.75
Formula
C38H44O8
CAS No.
2752-65-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (159.04 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol:
Solubility (In vivo)
Chemical Name
2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, (2Z)-
other peoduct :References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19405022
Gambogic Acid is a caged xanthone that is derived from Garcinia hanburyi and functions as a strong apoptotic inducer in many types of cancer cells by inhibiting human Bcl-2 family proteins and activating caspases. Gambogic Acid also blocks Kir2.1 channels with EC50 of ≤ 100 nM. Gambogic Acid significantly inhibits human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion, tube formation, and micro-vessel growth at nM concentration. | |
---|---|
In Vivo | Gambogic Acid effectively inhibits tumor angiogenesis and suppressed tumor growth with low side effects using metronomic chemotherapy with Gambogic Acid. The results indicated that iv injection of GGA 2, 4, and 8 mg/kg inhibited dramatically the growth of human hepatocellular cell line SMMC-7721 in nude mice from the early administration. |
Animal model | BALB/c nude mice bearing SMMC-7721 xenografts |
Formulation & Dosage | Intravenous injection, 2, 4, and 8 mg/kg, 3 times per week |
References | Acta Pharmacologica Sinica, 2004, 25: 769-774. |